- Headquarters
- Halifax
- Employees
- 51–200
- Founded
- 2007
- Website
- imv-inc.com
- Total Funding
- $26.7M
- Last Round
- $26.7M Venture RoundMar 2019
About
IMV Inc. is a clinical-stage immuno-oncology company developing a portfolio of therapies based on its proprietary DPX® immune-educating platform. The company's lead candidate maveropepimut-S (MVP-S) targets survivin, a cancer antigen overexpressed in advanced cancers, and is being evaluated in clinical trials for DLBCL, ovarian, bladder, and breast cancers.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account